查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1620370

Atosiban的全球市場規模:各類型，各用途，各地區，範圍及預測

Global Atosiban Market Size By Type (Injection, Concentrate), By Application (Hospitals, Online, Retail), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

Atosiban的市場規模與預測

2023 年Atosiban市場規模為 4.22 億美元，預計在 2024-2030 年預測期內複合年增長率為 11.5%，到 2030 年達到 8.41 億美元。由於孕婦早產、多胎妊娠、傳染病以及糖尿病和高血壓等慢性病的發生率不斷上升，Atosiban市場正在擴大。Atosiban全球市場報告提供了對市場的整體評估。它對關鍵細分市場、趨勢、市場推動因素、阻礙因素、競爭格局以及在市場中發揮關鍵作用的因素進行了全面分析。

全球Atosiban市場的定義

Atosiban是一種加壓素和催產素受體拮抗劑，是一種合成的非勝肽脫氨催產素類似物。由於其能夠透過抑制胞質內鈣的釋放和下調前列腺素的合成來減弱子宮收縮並增加子宮容受性，因此可用於預防或停止輔助生殖技術後的早產。

世界Atosiban市場概況

Atosiban是一種有效的子宮肌層收縮活化劑，對於足月和早產的開始都至關重要。早產率不斷增加，刺激了Atosiban市場的擴張。由於孕婦多胎妊娠、傳染病以及糖尿病和高血壓等慢性病的增加，其盛行率正在增加。

世界衛生組織 (WHO) 估計，每年有 1,500 萬嬰兒早產，而且這個數字還在增加。在 184 個國家，5% 至 18% 的新生兒早產。健康懷孕在很大程度上可以減少死亡和與早產相關的問題。透過使用現代且具有成本效益的治療方法，必須更頻繁地避免這些悲劇。

個人化治療的趨勢正在影響Atosiban市場。遺傳和藥物基因組學研究正在幫助確定可以增強Atosiban治療的患者特異性特徵。此外，遠距醫療和遠距患者監測等數位健康工具可以改變Atosiban的管理和追蹤方式，從而改善患者的治療結果。

一些限制和困難可能會阻礙市場擴張。相關監管問題、醫院基礎設施缺乏以及農村地區孕產婦護理教育不足正在限制市場擴張。

目錄

第1章 Atosiban的全球市場:簡介

  • 市場定義
  • 市場區隔
  • 調查計劃
  • 前提條件
  • 限制事項

第2章 VERIFIED MARKET RESEARCH的調查手法

  • 資料探勘
  • 資料的三角測量
  • Bottom-Up(由下而上)方法
  • Top-Down(由上而下)方法
  • 調查的流程
  • 產業專家的主要洞察
  • 資料來源

第3章 摘要整理

  • 市場概要
  • 生態學的製圖
  • 絕對的商機
  • 市場魅力
  • Atosiban的全球市場各地區分析(年複合成長率)
  • Atosiban的全球市場:各類型(USD Million)
  • Atosiban的全球市場:各用途(USD Million)
  • 今後的市場機會
  • 全球市場明細
  • 產品life line

第4章 Atosiban的全球市場展望

  • 全球Atosiban的演進
  • 促進因素
  • 阻礙因素
  • 機會
  • 波特的五力分析
  • 價值鏈分析
  • 價格分析
  • 宏觀經濟分析

第5章 Atosiban的全球市場:各類型

  • 概要
  • 注射劑
  • 濃縮液

第6章 Atosiban的全球市場:各用途

  • 概要
  • 醫院藥局
  • 線上藥局
  • 零售藥局

第7章 Atosiban的全球市場:各地區

  • 概要
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 南美
    • 巴西
    • 阿根廷
    • 其他南美國家
  • 中東·非洲
    • 阿拉伯聯合大公國
    • 沙烏地阿拉伯
    • 南非
    • 其他中東和非洲

第8章 Atosiban的全球市場:競爭情形

  • 概要
  • 各公司的市場排行榜
  • 主要的發展
  • 企業的地區足跡
  • 企業的產業足跡
  • ACE矩陣

第9章 企業簡介

  • Pfizer
  • Emcure Pharmaceuticals
  • Teva API
  • Ferring Pharmaceuticals
  • Sun Pharma
  • Shanghai Soho-Yiming Pharmaceuticals
  • EVER Pharma
  • Hangzhou Longshine Bio-Tech
  • Cayman Chemical
  • Neore Pharmaceutical
  • Hikma Pharmaceuticals
  • Lupin Pharmaceuticals
  • Bachem Group
  • Transo-Pharm Handels-GmbH
  • Rochem International Inc
  • Piramal Pharma Solutions

第10章 VERIFIED MARKET INTELLIGENCE

  • VERIFIED MARKET 關於INTELLIGENCE
  • 動態的資料的視覺化

第11章 附錄

  • 相關調查
簡介目錄
Product Code: 11638

Atosiban Market Size And Forecast

Atosiban Market size was valued at USD 422 Million in 2023 and is projected to reach USD 841 Million by 2030 , growing at a CAGR of 11.5% during the forecast period 2024-2030. The market for Atosiban is expanding due to rising rates of preterm delivery, numerous pregnancies, infections, and chronic illnesses like diabetes and high blood pressure among pregnant women. The Global Atosiban Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors playing a substantial role in the market.

Global Atosiban Market Definition

A competitive vasopressin and oxytocin receptor antagonist, Atosiban is a synthetic nonpeptide desamino-oxytocin analog. Because of its capacity to lessen contractions and increase uterine receptivity by reducing intracytoplasmic calcium release and downregulating prostaglandin synthesis, it is used after assisted reproduction to prevent preterm birth and to stop premature labor.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Atosiban Market Overview

Atosiban is a potent activator of myometrial contractions and is crucial at the start of both term and preterm labor. Preterm birth rates are rising, fueling the market expansion for Atosiban. Prevalence is fueled by increased multiple pregnancies, infections, and chronic illnesses, including diabetes and high blood pressure among pregnant women.

The World Health Organization estimates that 15 million babies are born preterm each year, which is increasing. Between 5% and 18% of newborns are born preterm in 184 nations. A healthy pregnancy is heavily responsible for reducing preterm birth-related fatalities and problems. With the use of modern, cost-effective therapies, these tragedies must be avoided more frequently.

The trend toward personalized treatment is impacting the market for Atosiban. Genetic and pharmacogenomic investigations are aiding the identification of patient-specific characteristics that can enhance Atosiban treatment. Additionally, digital health tools like telemedicine and remote patient monitoring alter how Atosiban is administered and tracked, leading to better patient outcomes.

Some limitations and difficulties may prevent the market from expanding. Related regulatory issues, a lack of hospital infrastructure, and insufficient prenatal care education in rural areas constrain the market's expansion.

Global Atosiban Market Segmentation Analysis

The Global Atosiban Market is segmented on the basis of Type, Application, and Geography.

By Type

Injection

Concentrate

Based on the Type, The market is segmented into Injection and Concentrate. The Injection segment is anticipated to dominate the Global Atosiban market. The quick beginning of the effect of Atosiban injection is well established. It is helpful for instances where urgent tocolysis (inhibition of uterine contractions) is required since it can swiftly stop uterine contractions and delay preterm labor.

By Application

Hospitals

Online

Retail

Based on the Application, The market is segmented into Hospitals, Online, and Retail. The Hospitals segment is anticipated to dominate the Global Atosiban market. Most of the time, hospitals employ Atosiban, especially in labor and delivery or maternity wards. It is given intravenously by medical personnel to expectant mothers going through preterm labor.

By Geography

North America

Europe

Asia Pacific

Rest of the world

Based on the Regional Analysis, Global Atosiban is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America will hold the largest Global Atosiban market as preterm birth is still a significant healthcare concern. In recent years, preterm birth rates have increased in the area. This pattern has increased demand for medications such as Atosiban, which postpone preterm labor and lessen the risks of premature birth.

Key Players

The "Global Atosiban Market" study report will provide valuable insight emphasizing the global market. The major players in the market are

Pfizer, Emcure Pharmaceuticals, Teva API, Ferring Pharmaceuticals, Sun Pharma, Shanghai Soho-Yiming Pharmaceuticals, EVER Pharma, Hangzhou Longshine Bio-Tech, Cayman Chemical, Neore Pharmaceutical, Hikma Pharmaceuticals, Lupin Pharmaceuticals, Bachem Group, Transo-Pharm Handels-GmbH, Rochem International Inc, Piramal Pharma Solutions.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Ace Matrix Analysis

The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features and innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories

Active, Cutting Edge, Emerging, and Innovators.

Market Attractiveness

The image of market attractiveness provided would further help to get information about the region that is majorly leading in the Global Atosiban Market. We cover the major impacting factors driving the industry growth in the given region.

Porter's Five Forces

The image provided would further help to get information about Porter's five forces framework, providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. Porter's five forces model can be used to assess the competitive landscape in the Global Atosiban Market, gauge the attractiveness of a certain sector, and assess investment possibilities.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL ATOSIBAN MARKET

  • 1.1 Market Definition
  • 1.2 Market Segmentation
  • 1.3 Research Timelines
  • 1.4 Assumptions
  • 1.5 Limitations

2 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 2.1 Data Mining
  • 2.2 Data Triangulation
  • 2.3 Bottom-Up Approach
  • 2.4 Top-Down Approach
  • 2.5 Research Flow
  • 2.6 Key Insights from Industry Experts
  • 2.7 Data Sources

3 EXECUTIVE SUMMARY

  • 3.1 Market Overview
  • 3.2 Ecology Mapping
  • 3.3 Absolute Market Opportunity
  • 3.4 Market Attractiveness
  • 3.5 Global Atosiban Market Geographical Analysis (CAGR %)
  • 3.6 Global Atosiban Market, By Type (USD Million)
  • 3.7 Global Atosiban Market, By Application (USD Million)
  • 3.8 Future Market Opportunities
  • 3.9 Global Market Split
  • 3.10 Product Life Line

4 GLOBAL ATOSIBAN MARKET OUTLOOK

  • 4.1 Global Atosiban Evolution
  • 4.2 Drivers
    • 4.2.1 Driver 1
    • 4.2.2 Driver 2
  • 4.3 Restraints
    • 4.3.1 Restraint 1
    • 4.3.2 Restraint 2
  • 4.4 Opportunities
    • 4.4.1 Opportunity 1
    • 4.4.2 Opportunity 2
  • 4.5 Porters Five Force Model
  • 4.6 Value Chain Analysis
  • 4.7 Pricing Analysis
  • 4.8 Macroeconomic Analysis

5 GLOBAL ATOSIBAN MARKET, BY TYPE

  • 5.1 Overview
  • 5.2 Injection
  • 5.3 Concentrate

6 GLOBAL ATOSIBAN MARKET, BY APPLICATION

  • 6.1 Overview
  • 6.2 Hospital Pharmacies
  • 6.3 Online Pharmacies
  • 6.4 Retail Pharmacies

7 GLOBAL ATOSIBAN MARKET, BY GEOGRAPHY

  • 7.1 Overview
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 U.K.
    • 7.3.3 France
    • 7.3.4 Italy
    • 7.3.5 Spain
    • 7.3.6 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Rest of Asia Pacific
  • 7.5 Latin America
    • 7.5.1 Brazil
    • 7.5.2 Argentina
    • 7.5.3 Rest of Latin America
  • 7.6 Middle-East and Africa
    • 7.6.1 UAE
    • 7.6.2 Saudi Arabia
    • 7.6.3 South Africa
    • 7.6.4 Rest of Middle-East and Africa

8 GLOBAL Atosiban MARKET COMPETITIVE LANDSCAPE

  • 8.1 Overview
  • 8.2 Company Market Ranking
  • 8.3 Key Developments
  • 8.4 Company Regional Footprint
  • 8.5 Company Industry Footprint
  • 8.6 ACE Matrix

9 COMPANY PROFILES

  • 9.1 Pfizer
    • 9.1.1 Company Overview
    • 9.1.2 Company Insights
    • 9.1.3 Product Benchmarking
    • 9.1.4 Key Development
    • 9.1.5 Winning Imperatives
    • 9.1.6 Current Focus & Strategies
    • 9.1.7 Threat from Competition
    • 9.1.8 SWOT Analysis
  • 9.2 Emcure Pharmaceuticals
    • 9.2.1 Overview
    • 9.2.2 Financial Performance
    • 9.2.3 Product Outlook
    • 9.2.4 Key Developments
  • 9.3 Teva API
    • 9.3.1 Overview
    • 9.3.2 Financial Performance
    • 9.3.3 Product Outlook
    • 9.3.4 Key Developments
  • 9.4 Ferring Pharmaceuticals
    • 9.4.1 Overview
    • 9.4.2 Financial Performance
    • 9.4.3 Product Outlook
    • 9.4.4 Key Developments
  • 9.5 Sun Pharma
    • 9.5.1 Overview
    • 9.5.2 Financial Performance
    • 9.5.3 Product Outlook
    • 9.5.4 Key Developments
  • 9.6 Shanghai Soho-Yiming Pharmaceuticals
    • 9.6.1 Overview
    • 9.6.2 Financial Performance
    • 9.6.3 Product Outlook
    • 9.6.4 Key Developments
  • 9.7 EVER Pharma
    • 9.7.1 Overview
    • 9.7.2 Financial Performance
    • 9.7.3 Product Outlook
    • 9.7.4 Key Developments
  • 9.8 Hangzhou Longshine Bio-Tech
    • 9.8.1 Overview
    • 9.8.2 Financial Performance
    • 9.8.3 Product Outlook
    • 9.8.4 Key Developments
  • 9.9 Cayman Chemical
    • 9.9.1 Overview
    • 9.9.2 Financial Performance
    • 9.9.3 Product Outlook
    • 9.9.4 Key Developments
  • 9.10 Neore Pharmaceutical
    • 9.10.1 Overview
    • 9.10.2 Financial Performance
    • 9.10.3 Product Outlook
    • 9.10.4 Key Developments
  • 9.11 Hikma Pharmaceuticals
    • 9.11.1 Overview
    • 9.11.2 Financial Performance
    • 9.11.3 Product Outlook
    • 9.11.4 Key Developments
  • 9.12 Lupin Pharmaceuticals
    • 9.12.1 Overview
    • 9.12.2 Financial Performance
    • 9.12.3 Product Outlook
    • 9.12.4 Key Developments
  • 9.13 Bachem Group
    • 9.13.1 Overview
    • 9.13.2 Financial Performance
    • 9.13.3 Product Outlook
    • 9.13.4 Key Developments
  • 9.14 Transo-Pharm Handels-GmbH
    • 9.14.1 Overview
    • 9.14.2 Financial Performance
    • 9.14.3 Product Outlook
    • 9.14.4 Key Developments
  • 9.15 Rochem International Inc
    • 9.15.1 Overview
    • 9.15.2 Financial Performance
    • 9.15.3 Product Outlook
    • 9.15.4 Key Developments
  • 9.16 Piramal Pharma Solutions
    • 9.16.1 Overview
    • 9.16.2 Financial Performance
    • 9.16.3 Product Outlook
    • 9.16.4 Key Developments

10. VERIFIED MARKET INTELLIGENCE

  • 10.1 About Verified Market Intelligence
  • 10.2 Dynamic Data Visualization

11 Appendix

  • 11.1 Related Research